Search research articles
Contact Us
Filters
Showing results (231-240 of 252) with videos related to
Page
of 26
Sort By:
Science (New York, N.Y.)
|
September 2, 2006
Cancer regression in patients after transfer of genetically engineered lymphocytes
Richard A Morgan, Mark E Dudley, John R Wunderlich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 16, 2017
Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3
Yong-Chen Lu, Linda L Parker, Tangying Lu, et al.
Blood
|
December 14, 2011
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
James N Kochenderfer, Mark E Dudley, Steven A Feldman, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
June 27, 2003
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
Giao Q Phan, James C Yang, Richard M Sherry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 5, 2002
Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma
John F Toso, Vee J Gill, Patrick Hwu, et al.
Journal of Medicinal Chemistry
|
February 20, 2007
Discovery of Ecopladib, an indole inhibitor of cytosolic phospholipase A2alpha
Katherine L Lee, Megan A Foley, Lihren Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 20, 2015
Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma
Ling Zhang, Richard A Morgan, Joal D Beane, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 8, 2013
Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma
Mark E Dudley, Colin A Gross, Robert P T Somerville, et al.
The Lancet. Oncology
|
April 12, 2017
Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study
Smita S Chandran, Robert P T Somerville, James C Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 25, 2014
A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response
Paul F Robbins, Sadik H Kassim, Thai L N Tran, et al.
Page
of 26
Search research articles
Search
Showing results (231-240 of 252) with videos related to
Sort By:
Page
of 26
Science (New York, N.Y.)
|
September 2, 2006
Cancer regression in patients after transfer of genetically engineered lymphocytes
Richard A Morgan, Mark E Dudley, John R Wunderlich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 16, 2017
Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3
Yong-Chen Lu, Linda L Parker, Tangying Lu, et al.
Blood
|
December 14, 2011
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
James N Kochenderfer, Mark E Dudley, Steven A Feldman, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
June 27, 2003
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
Giao Q Phan, James C Yang, Richard M Sherry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 5, 2002
Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma
John F Toso, Vee J Gill, Patrick Hwu, et al.
Journal of Medicinal Chemistry
|
February 20, 2007
Discovery of Ecopladib, an indole inhibitor of cytosolic phospholipase A2alpha
Katherine L Lee, Megan A Foley, Lihren Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 20, 2015
Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma
Ling Zhang, Richard A Morgan, Joal D Beane, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 8, 2013
Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma
Mark E Dudley, Colin A Gross, Robert P T Somerville, et al.
The Lancet. Oncology
|
April 12, 2017
Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study
Smita S Chandran, Robert P T Somerville, James C Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 25, 2014
A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response
Paul F Robbins, Sadik H Kassim, Thai L N Tran, et al.
Page
of 26